Article in Molecules (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
13 authors.
Ana JesusAssociate Laboratory i4HB-Institute for Health and Bioeconomy, University of Porto, 4050-313 Porto, Portugal.ORCID 0000-0001-7425-9750
Marta Correia-da-SilvaLaboratory of Organic and Pharmaceutical Chemistry, Department of Chemical Sciences, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal.ORCID 0000-0003-4150-8532
Catarina ConfrariaLaboratory of Organic and Pharmaceutical Chemistry, Department of Chemical Sciences, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal.
Sílvia SilvaLaboratory of Pharmaceutical Technology, Department of Drug Sciences, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal.
Gonçalo BritesFaculty of Pharmacy, University of Coimbra, 3004-531 Coimbra, Portugal.ORCID 0000-0003-3705-673X
Ana I SebastiãoFaculty of Pharmacy, University of Coimbra, 3004-531 Coimbra, Portugal.ORCID 0000-0002-1687-2968
Mylène CarrascalCNC-Center for Neurosciences and Cell Biology, 3004-504 Coimbra, Portugal.ORCID 0000-0002-3391-543X
Madalena PintoLaboratory of Organic and Pharmaceutical Chemistry, Department of Chemical Sciences, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal.ORCID 0000-0002-4676-1409
Honorina CidadeLaboratory of Organic and Pharmaceutical Chemistry, Department of Chemical Sciences, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal.ORCID 0000-0003-0715-1779
Paulo CostaAssociate Laboratory i4HB-Institute for Health and Bioeconomy, University of Porto, 4050-313 Porto, Portugal.ORCID 0000-0002-1152-3398
Maria T CruzFaculty of Pharmacy, University of Coimbra, 3004-531 Coimbra, Portugal.ORCID 0000-0001-9846-6754
Emília SousaLaboratory of Organic and Pharmaceutical Chemistry, Department of Chemical Sciences, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal.ORCID 0000-0002-5397-4672
Isabel F AlmeidaAssociate Laboratory i4HB-Institute for Health and Bioeconomy, University of Porto, 4050-313 Porto, Portugal.ORCID 0000-0002-1498-048X
Funding
Fundação para a Ciência e a Tecnologia Gonçalo Brites acknowledges his Ph.D. grant with reference PD/BDE/142926/2018Fundação para a Ciência e Tecnologia Ana I. Sebastião acknowledges her Ph.D. grant with reference DOI: 10.54499/2021.04586.BDFundação para a Ciência e Tecnologia Ana Jesus acknowledges her Ph.D. grant with reference UI/BD/151319/2021 with DOI: 10.54499/UI/BD/151319/2021Fundação para a Ciência e Tecnologia in the scope of the project UIDP/04378/2020 (DOI: 10.54499/UIDP/04378/2020) and UIDB/04378/2020 (DOI: 10.54499/UIDB/04378/2020) of the Research Unit on Applied Molecular Biosciences-UCIBIO and the project LA/P/0140/2020 (DOI: 10.54499/LA/P/0140/2020) of tFundação para a Ciência e Tecnologia the European Regional Development Fund (ERDF), through the Centro 2020 Regional Operational Programme under project CENTRO-01-0145-FEDER-000012 (HealthyAging2020)Fundação para a Ciência e Tecnologia the projects UIDP/04539/2020, and UIDP/04423/2020 (Group of Marine Natural Products and Medicinal Chemistry-CIIMAR), and the projects UIDP/04539/2020 and LA/P/0058/2020 from CIBB
6 · The paper itself
Abstract
The pursuit of cosmetic ingredients with proven efficacy and safety that meet consumer needs drives the advancement of new products. Ascorbic acid (AA) is utilized in cosmetic products, predominantly for its potent antioxidant properties. Nonetheless, its instability compromises its efficacy. In this work, ascorbyl 2-
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.